Is there any benefit to adding bevacizumab to chemo-immunotherapy in metastatic NSCLC?

In the ITT population of the Impower 150 trial the median OS was 19.2 mo on arm B (Atezo + chemo + bev) and 14.7 mo on arm C (chemo + bev) with a Significant HR of 0.78 but the mOS in arm A (atezo + chemo) was 19.4 mo with no planned comparison to arm B but seems not to be significant. So the presenters would say there were no plans for this comparison but survival in arms A and B seem quite similar.

With further follow-up we may see differences in mOS between arms A+B of IMpower 150 (which may not be surprising given what we know about the addition of bevacizumab to paclitaxel/carboplatin from ECOG 4599), and no statistical comparison of arms A+B was planned as part of this trial. The more relevant question is how either of these regimens could supplant pembrolizumab/pemetrexed/carboplatin as the preferred chemoimmunotherapy combination for front-line non-squamous NSCLC? Not likely since pe...

There appears to be early hints that adding bevacizumab may have some role based on the comparative HRs.

In the ITT-WT population, the HR for OS was 0.78 (95% CI 0.64-0.96, p=0.016) with the bev+IO+Chemo arm in relation to control chemo+Bev group compared to HR for OS of 0.88 (95% CI 0.72-1.08, p=0.2) in the (non-bev)IO+chemo arm, even though median numbers appear quite similar. With longer follow-up, a difference may or may not emerge to show significance, partly influenced by % of patients rec...